Experimental study of neuropsychotropic activity

Abstract

Objective. To study the neuropsychotropic activity of 2,4-dioxobutanoic acid derivatives containing a fragment of benzimidazole as well as to determine the relationship between the structure of substances and their biological effects.

Materials and methods. The spectrum of neuropsychotropic activity of 2,4-dioxobutanoic acid derivatives with benzimidazole was studied on experimental animals using the «open field», «black-and-white camera», and «extrapolation deliverance» tests.

Results. A compound with potential anxiolytic properties has been identified. The dependence of the manifestation of anxiogenic or anxiolytic properties in the presence of mono- or bicyclic arenes in the structure, respectively, is shown.

Conclusions. 2,4-Dioxobutane acids containing a fragment of benzimidazole are of interest for the search for substances with neuropsychotropic activity. The results of the “structure-activity” analysis should be used in further targeted synthesis.

Keywords

2 / 4-Dioxobutanoic acids / benzimidazole / neuropsychotropic activity

References

[1] Brishty S.R., Hossain M.J., Khandaker M.U., Faruque M.R.I., Osman H., Rahman S.M.A. A Comprehensive Account on Recent Progress in Pharmacological Activities of Benzimidazole Derivatives. Front Pharmacol 2021; 12: 762–807.

[2] Brishty S.R., Hossain M.J., Khandaker M.U., Faruque M.R.I., Osman H., Rahman S.M.A. A Comprehensive Account on Recent Progress in Pharmacological Activities of Benzimidazole Derivatives. Front Pharmacol. 2021; 12: 762–807.

[3] Duarte C.D., Barreiro E.J., Fraga C.A. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007; 7 (11): 1108–19.

[4] Hauser A.S., Attwood M.M., Rask-Andersen M., Schiöth H.B., Gloriam D.E. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017; 16 (12): 829–842.

[5] Encyclopedia of medicines 2020 of the Russian register of medicines. Moscow: VEDANTA 2019: 1536 (in Russian).

[6] Регистр лекарственных средств России. РЛС. Энциклопедия лекарств. 30-й вып. М. ВЕДАНТА 2021; 1536.

[7] Pulina N.A., Sobin F.V., Yushkova T.A., Krasnova A.I., Yushkov V.V. 2-Hydroxy-4-methylphenyl-4-oxo-2-butenoate of thiazonyl ammonium, possessing hypoglycemic and nootropic activity: Patent RF № 2512291 from 26.07.2011: available at: http://www.findpatent.ru/patent/251/2512291.html (in Russian).

[8] Пулина Н.А., Собин Ф.В., Юшкова Т.А., Краснова А.И., Юшков В.В. 2-Гидрокси-4-метилфенил-4-оксо-2-бутеноат тиазониламмония, обладающий гипогликемической и ноотропной активностью: патент № 2512291 от 26.07.2011: available at: http://www.findpatent.ru/patent/251/2512291.html

[9] Pulina N.A., Sobin F.V., Syropyatov B.Ya., Mokin P.A., Kovaleva M. Yu. Synthesis and anticoagulant activity of α-oxocarbonic acid derivatives. Pharm. Chem. J. 2012; 46 (12): 15–18 (in Russian).

[10] Пулина Н.А., Собин Ф.В., Сыропятов Б.Я., Мокин П.А., Ковалева М.Ю. Синтез и антикоагулянтная активность производных α-оксокарбоновых кислот. Химико-фармацевтический журнал 2012; 46 (12): 15–18.

[11] State Pharmacopoeia of the Russian Federation of the Ministry of Health of the Russian Federation 14th ed. Мoscow 2018: 1: 1814 (in Russian).

[12] Государственная фармакопея Российской Федерации Министерства здравоохранения Российской Федерации XIV изд. М., 2018; 1: 1814.

[13] Guidelines for conducting preclinical studies of drugs. Part One. Pod red. A.N. Mironova. Мoscow: Grif i K. 2013; 944 (in Russian).

[14] Руководство по проведению доклинических исследований лекарственных средств. Часть первая. Под ред. А.Н. Миронова. М.: Гриф и К. 2013; 944.

Funding

Пермский научно-образовательный центр «Рациональное недропользование»Perm Scientific and Educational Center "Rational Subsoil Use"

RIGHTS & PERMISSIONS

Krasnova A.I., Pulina N.A., Polezhaeva V.D.